Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Patrick Alexander Ott, Ph.D., M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA229261 (OTT, PATRICK ALEXANDER) Sep 6, 2018 - Aug 31, 2023
    Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J, Qazi T, Elias R, Vora KB, Ruan AB, Martin-Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi FS, Rahma OE. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020 Aug 15; 126(16):3758-3767. PMID: 32567084.
  2. Grover S, Ruan AB, Srivoleti P, Giobbie-Hurder A, Braschi-Amirfarzan M, Srivastava A, Buchbinder EI, Ott PA, Kehl KL, Awad MM, Hodi FS, Rahma OE. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. JCO Oncol Pract. 2020 May 13; JOP1900672. PMID: 32401685.
  3. Mehnert JM, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, Doi T, Ott PA, Pishvaian MJ, Puzanov I, Aung KL, Hsu C, Le Tourneau C, Hollebecque A, Élez E, Tamura K, Gould M, Yang P, Stein K, Piha-Paul SA. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer. 2020 Jul 01; 126(13):3021-3030. PMID: 32320048.
  4. Kumar V, Shinagare AB, Rennke HG, Ghai S, Lorch JH, Ott PA, Rahma OE. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature. Oncologist. 2020 Jun; 25(6):505-514. PMID: 32043699.
  5. Rao PK, Barker C, Coit DG, Joseph RW, Materin M, Rengan R, Sosman J, Thompson JA, Albertini MR, Boland G, Carson Iii WE, Contreras C, Daniels GA, DiMaio D, Durham A, Fields RC, Fleming MD, Galan A, Gastman B, Grossman K, Guild V, Johnson D, Karakousis G, Lange JR, Margolin K, Nath S, Olszanski AJ, Ott PA, Ross MI, Salama AK, Skitzki J, Swetter SM, Wuthrick E, McMillian NR, Engh A. NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. J Natl Compr Canc Netw. 2020 02; 18(2):120-131. PMID: 32023525.
  6. Anandappa AJ, Wu CJ, Ott PA. Directing Traffic: How to Effectively Drive T Cells into Tumors. Cancer Discov. 2020 02; 10(2):185-197. PMID: 31974169.
  7. Truex NL, Holden RL, Wang BY, Chen PG, Hanna S, Hu Z, Shetty K, Olive O, Neuberg D, Hacohen N, Keskin DB, Ott PA, Wu CJ, Pentelute BL. Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy. Sci Rep. 2020 01 20; 10(1):723. PMID: 31959774.
  8. Chau I, Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Sanchez T, Maglinte GA, Laurie M, Abraham P, Patel D, Shangguan T. Correction to: Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer. Gastric Cancer. 2020 01; 23(1):142. PMID: 31679092.
  9. Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, Bennouna J, Kim DW, Xu L, Krishnan S, Norwood K, Ott PA. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol. 2020 Apr; 15(4):618-627. PMID: 31870883.
  10. Krimphove MJ, Tully KH, Friedlander DF, Marchese M, Ravi P, Lipsitz SR, Kilbridge KL, Kibel AS, Kluth LA, Ott PA, Choueiri TK, Trinh QD. Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. J Immunother Cancer. 2019 11 07; 7(1):289. PMID: 31699149.
  11. Pavlick A, Blazquez AB, Meseck M, Lattanzi M, Ott PA, Marron TU, Holman RM, Mandeli J, Salazar AM, McClain CB, Gimenez G, Balan S, Gnjatic S, Sabado RL, Bhardwaj N. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. Cancer Immunol Res. 2020 Jan; 8(1):70-80. PMID: 31699709.
  12. Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, Antonia SJ, Ascierto PA, Moreno V, Atmaca A, Salvagni S, Taylor M, Amin A, Camidge DR, Horn L, Calvo E, Li A, Lin WH, Callahan MK, Spigel DR. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. J Thorac Oncol. 2020 Mar; 15(3):426-435. PMID: 31629915.
  13. Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Maglinte GA, Abraham P, Patel D, Shangguan T, Chau I. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clin Colorectal Cancer. 2020 Mar; 19(1):32-38.e3. PMID: 31813769.
  14. Chau I, Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Sanchez T, Maglinte GA, Laurie M, Abraham P, Patel D, Shangguan T. Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer. Gastric Cancer. 2020 01; 23(1):133-141. PMID: 31549264.
  15. Fastow E, Cook S, Dean P, Ott P, Wilson J, Yoon H, Dietz T, Bateman F, Al-Sheikhly M. Single-Step Synthesis of Atmospheric CO2 Sorbents through Radiation-Induced Graft Polymerization on Commercial-Grade Fabrics. Radiat Res. 2019 08; 192(2):219-230. PMID: 31246533.
  16. Ott PA, Dotti G, Yee C, Goff SL. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e70-e78. PMID: 31099621.
  17. Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, Daniels GA, DiMaio D, Fields RC, Fleming MD, Freeman M, Galan A, Gastman B, Guild V, Johnson D, Joseph RW, Lange JR, Nath S, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Wuthrick E, McMillian NR, Engh AM. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 04 01; 17(4):367-402. PMID: 30959471.
  18. Fareed MM, Pike LRG, Bang A, Huynh MA, Taylor A, Spektor A, Awad MM, Ott PA, Krishnan M, Balboni TA, Schoenfeld JD. Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy. Front Oncol. 2019; 9:199. PMID: 30984622.
  19. Naik GS, Waikar SS, Johnson AEW, Buchbinder EI, Haq R, Hodi FS, Schoenfeld JD, Ott PA. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer. 2019 03 29; 7(1):89. PMID: 30922394.
  20. Ott PA, Wu CJ. Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors. Cancer Discov. 2019 04; 9(4):476-481. PMID: 30862723.
  21. Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, Alizadeh AR, Salama AK, He Y, Hawthorne TR, Bagley RG, Zhang J, Turner CD, Hamid O. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer. 2019 04 01; 125(7):1113-1123. PMID: 30690710.
    Citations:    Fields:    
  22. Ott PA. Intralesional Cancer Immunotherapies. Hematol Oncol Clin North Am. 2019 04; 33(2):249-260. PMID: 30832998.
  23. Ott PA. Immunotherapy: An Old and New Modality for the Treatment of Cancer. Hematol Oncol Clin North Am. 2019 04; 33(2):xi-xii. PMID: 30833004.
  24. Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiocca EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239. PMID: 30568305.
    Citations:    Fields:    
  25. Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, Rugo HS, Cohen RB, O'Neil BH, Mehnert JM, Lopez J, Doi T, van Brummelen EMJ, Cristescu R, Yang P, Emancipator K, Stein K, Ayers M, Joe AK, Lunceford JK. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2019 02 01; 37(4):318-327. PMID: 30557521.
    Citations:    Fields:    
  26. Varga A, Piha-Paul S, Ott PA, Mehnert JM, Berton-Rigaud D, Morosky A, Yang P, Ruman J, Matei D. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. Gynecol Oncol. 2019 02; 152(2):243-250. PMID: 30522700.
    Citations:    Fields:    
  27. Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS. Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018 12; 28(6):605-610. PMID: 30211813.
    Citations:    Fields:    
  28. Barroso-Sousa R, Ott PA. Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors. Curr Oncol Rep. 2018 11 15; 21(1):1. PMID: 30498900.
  29. Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell. 2018 11 12; 34(5):775-791.e3. PMID: 30423297.
    Citations:    Fields:    
  30. Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, Ashenberg O, Ott PA, Buchbinder EI, Haq R, Hodi FS, Boland GM, Sullivan RJ, Frederick DT, Miao B, Moll T, Flaherty KT, Herlyn M, Jenkins RW, Thummalapalli R, Kowalczyk MS, Cañadas I, Schilling B, Cartwright ANR, Luoma AM, Malu S, Hwu P, Bernatchez C, Forget MA, Barbie DA, Shalek AK, Tirosh I, Sorger PK, Wucherpfennig K, Van Allen EM, Schadendorf D, Johnson BE, Rotem A, Rozenblatt-Rosen O, Garraway LA, Yoon CH, Izar B, Regev A. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24. PMID: 30388455.
    Citations:    Fields:    
  31. Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018 10 12; 362(6411). PMID: 30309915.
    Citations:    Fields:    Translation:HumansCells
  32. Pike LRG, Bang A, Mahal BA, Taylor A, Krishnan M, Spektor A, Cagney DN, Aizer AA, Alexander BM, Rahma O, Balboni T, Ott PA, Hodi FS, Schoenfeld JD. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):142-151. PMID: 30227198.
    Citations:    Fields:    
  33. Dobry AS, Zogg CK, Hodi FS, Smith TR, Ott PA, Iorgulescu JB. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. Cancer Immunol Immunother. 2018 Dec; 67(12):1833-1844. PMID: 30191256.
    Citations:    Fields:    Translation:Humans
  34. Hu Z, Anandappa AJ, Sun J, Kim J, Leet DE, Bozym DJ, Chen C, Williams L, Shukla SA, Zhang W, Tabbaa D, Steelman S, Olive O, Livak KJ, Kishi H, Muraguchi A, Guleria I, Stevens J, Lane WJ, Burkhardt UE, Fritsch EF, Neuberg D, Ott PA, Keskin DB, Hacohen N, Wu CJ. A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood. 2018 11 01; 132(18):1911-1921. PMID: 30150207.
    Citations:    Fields:    
  35. Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018 10 01; 36(28):2836-2844. PMID: 30110194.
    Citations:    Fields:    
  36. Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, Wallmark JM, Keam B, Delord JP, Aggarwal R, Gould M, Yang P, Keefe SM, Piha-Paul SA. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018 08 01; 29(8):1807-1813. PMID: 29992241.
    Citations: 1     Fields:    
  37. Morgan FC, Duran J, Fraile B, Karia PS, Lin JY, Ott PA, Ruiz ES, Wang DM, Zhang Y, Schmults CD. A comparison of skin cancer screening and treatment costs at a Massachusetts cancer center, 2008 versus 2013. J Am Acad Dermatol. 2018 Nov; 79(5):921-928. PMID: 30322559.
    Citations:    Fields:    Translation:Humans
  38. Elias R, Giobbie-Hurder A, McCleary NJ, Ott P, Hodi FS, Rahma O. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer. 2018 04 04; 6(1):26. PMID: 29618381.
    Citations: 2     Fields:    
  39. Rugo HS, Delord JP, Im SA, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Le Tourneau C, van Brummelen EMJ, Varga A, Salgado R, Loi S, Saraf S, Pietrangelo D, Karantza V, Tan AR. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Clin Cancer Res. 2018 06 15; 24(12):2804-2811. PMID: 29559561.
    Citations: 2     Fields:    
  40. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402. PMID: 29542692.
    Citations: 1     Fields:    
  41. Ott PA. Immunotherapy: Immune-modified response criteria - an iterative learning process? Nat Rev Clin Oncol. 2018 05; 15(5):267-268. PMID: 29532797.
    Citations:    Fields:    
  42. Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer. 2018 03 15; 124(6):1111-1121. PMID: 29313945.
    Citations:    Fields:    
  43. Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018 03; 18(3):168-182. PMID: 29226910.
    Citations: 8     Fields:    
  44. Barroso-Sousa R, Ott PA. PD-1 inhibitors in endometrial cancer. Oncotarget. 2017 Dec 05; 8(63):106169-106170. PMID: 29290936.
    Citations: 1     Fields:    
  45. Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215. PMID: 29101162.
    Citations: 4     Fields:    
  46. Frenel JS, Le Tourneau C, O'Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas S, Saraf S, Rangwala R, Varga A. Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol. 2017 Dec 20; 35(36):4035-4041. PMID: 29095678.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  47. Lee H, Hodi FS, Giobbie-Hurder A, Ott PA, Buchbinder EI, Haq R, Tolaney S, Barroso-Sousa R, Zhang K, Donahue H, Davis M, Gargano ME, Kelley KM, Carroll RS, Kaiser UB, Min L. Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer Immunol Res. 2017 12; 5(12):1133-1140. PMID: 29079654.
    Citations: 2     Fields:    Translation:HumansCells
  48. Ott PA, Soria JC. Reply to F. Tomao et al. J Clin Oncol. 2017 11 01; 35(31):3633-3634. PMID: 28880745.
    Citations:    Fields:    
  49. Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S, Piperdi B, Mehnert JM. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017 Dec 01; 35(34):3823-3829. PMID: 28813164.
    Citations: 18     Fields:    Translation:HumansCTClinical Trials
  50. Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS, Ott PA, Choueiri TK. Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer. 2017; 5:66. PMID: 28815046.
  51. Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS, Ott PA, Choueiri TK. Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer. 2017 08 15; 5(1):66. PMID: 28807048.
    Citations:    Fields:    Translation:Humans
  52. Moreira RB, Hamieh L, Gjini E, Lako A, Krajewski KM, Yoon CH, Ott PA. Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab. J Immunother Cancer. 2017 07 18; 5(1):61. PMID: 28716097.
    Citations:    Fields:    Translation:Humans
  53. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221. PMID: 28678778.
    Citations: 115     Fields:    Translation:HumansCellsCTClinical Trials
  54. Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, Rawal B, Spektor A, Krishnan M, Cagney D, Alexander B, Aizer AA, Buchbinder E, Awad M, Gandhi L, Hodi FS, Schoenfeld JD. Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 07; 124(1):98-103. PMID: 28662869.
    Citations: 4     Fields:    Translation:Humans
  55. Goldman C, Tchack J, Robinson EM, Han SW, Moran U, Polsky D, Berman RS, Shapiro RL, Ott PA, Osman I, Zhong H, Pavlick AC, Wilson MA. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care. Oncology. 2017; 93(3):164-176. PMID: 28601879.
    Citations:    Fields:    Translation:Humans
  56. Nishino M, Giobbie-Hurder A, Manos MP, Bailey N, Buchbinder EI, Ott PA, Ramaiya NH, Hodi FS. Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clin Cancer Res. 2017 Aug 15; 23(16):4671-4679. PMID: 28592629.
    Citations: 8     Fields:    Translation:Humans
  57. Ott P, Calvo E, Sharma P, Jaeger D, Ascierto P, Chau I, Bendell J, Peltola K, Taylor M, Tschaika M, Dorange C, Janjigian Y, Le D. Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study. Ann Oncol. 2017 Jun; 28 Suppl 3:iii139. PMID: 32135767.
  58. Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, Saraf S, Chen M, Soria JC. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. J Clin Oncol. 2017 Aug 01; 35(22):2535-2541. PMID: 28489510.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  59. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EMJ, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017 05 01; 28(5):1036-1041. PMID: 28453692.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  60. Cagney DN, Alexander BM, Hodi FS, Buchbinder EI, Ott PA, Aizer AA. Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol. 2017 05; 133(1):221. PMID: 28527005.
    Citations:    Fields:    
  61. Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman JA, Johnson DB, Buchbinder EI. Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunol Res. 2017 05; 5(5):357-362. PMID: 28396509.
    Citations: 3     Fields:    Translation:Humans
  62. Garcia-Neuer M, Marmarelis ME, Jangi SR, Luke JJ, Ibrahim N, Davis M, Weinberg J, Donahue H, Bailey N, Hodi FS, Buchbinder EL, Ott PA. Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients. Cancer Immunol Res. 2017 04; 5(4):286-291. PMID: 28373217.
    Citations:    Fields:    Translation:Humans
  63. Hermel DJ, Ott PA. Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. Cancer Metastasis Rev. 2017 03; 36(1):51. PMID: 28326450.
    Citations: 1     Fields:    
  64. Hermel DJ, Ott PA. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. Cancer Metastasis Rev. 2017 03; 36(1):43-50. PMID: 28181070.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  65. De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res. 2017 04; 5(4):312-318. PMID: 28246107.
    Citations: 14     Fields:    
  66. Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J Immunother Cancer. 2017; 5:16. PMID: 28239469.
    Citations: 37     Fields:    Translation:HumansAnimals
  67. George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, Van Allen EM. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017 02 21; 46(2):197-204. PMID: 28228279.
    Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
  68. Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, Spektor A, Krishnan M, Ott PA, Balboni TA, Hodi FS, Schoenfeld JD. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 06 01; 98(2):344-351. PMID: 28463153.
    Citations: 14     Fields:    Translation:Humans
  69. Ott PA, Piha-Paul SA, Munster P, Pishvaian MJ, van Brummelen EM, Cohen RB, Gomez-Roca C, Ejadi S, Stein M, Chan E, Simonelli M, Morosky A, Saraf S, Emancipator K, Koshiji M, Bennouna J. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017 Feb 07. PMID: 28168292.
  70. Mouw KW, Cleary JM, Reardon B, Pike J, Braunstein LZ, Kim J, Amin-Mansour A, Miao D, Damish A, Chin J, Ott PA, Fuchs CS, Martin NE, Getz G, Carter S, Mamon HJ, Hornick JL, Van Allen EM, D'Andrea AD. Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. Clin Cancer Res. 2017 Jun 15; 23(12):3214-3222. PMID: 27852700.
    Citations: 2     Fields:    Translation:Humans
  71. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 10 10; 34(29):3562-3569. PMID: 27528724.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  72. Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016 Nov; 17(11):1590-1598. PMID: 27733243.
    Citations: 60     Fields:    Translation:HumansCTClinical Trials
  73. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016 Nov; 17(11):1558-1568. PMID: 27622997.
    Citations: 99     Fields:    Translation:HumansCTClinical Trials
  74. Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016 Dec 15; 22(24):6051-6060. PMID: 27535979.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  75. Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Nov 15; 122(21):3354-3362. PMID: 27533633.
    Citations: 18     Fields:    Translation:Humans
  76. Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016 Nov 15; 122(21):3344-3353. PMID: 27533448.
    Citations: 23     Fields:    Translation:Humans
  77. Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016; 4:50. PMID: 27532025.
    Citations: 39     Fields:    
  78. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. NCCN Guidelines Insights: Melanoma, Version 3.2016. J Natl Compr Canc Netw. 2016 08; 14(8):945-58. PMID: 27496110.
    Citations: 9     Fields:    Translation:Humans
  79. Cagney DN, Alexander BM, Hodi FS, Buchbinder EI, Ott PA, Aizer AA. Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol. 2016 09; 129(3):389-393. PMID: 27401151.
    Citations:    Fields:    Translation:Humans
  80. Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, Le DT, Lipson EJ, Glezerman IG, Wolchok J, Cornell LD, Feldman P, Stokes MB, Zapata SA, Hodi FS, Ott PA, Yamashita M, Leaf DE. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016 09; 90(3):638-47. PMID: 27282937.
    Citations: 26     Fields:    Translation:Humans
  81. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016 Jul; 17(7):883-895. PMID: 27269741.
    Citations: 118     Fields:    Translation:HumansCTClinical Trials
  82. Ott PA, Hodi FS. Talimogene Laherparepvec for the Treatment of Advanced Melanoma. Clin Cancer Res. 2016 07 01; 22(13):3127-31. PMID: 27146699.
    Citations: 12     Fields:    Translation:HumansCells
  83. Marmarelis ME, Davis MR, Sethi NS, Krajewksi KM, McKay RR, Choueiri TK, Ott PA. Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. J Immunother Cancer. 2016; 4:26. PMID: 27099755.
    Citations:    Fields:    
  84. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016 Feb; 2(2):234-40. PMID: 26633184.
    Citations: 56     Fields:    Translation:Humans
  85. Ott PA. Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapy. Ann Transl Med. 2015 Nov; 3(20):313. PMID: 26697473.
  86. Ott PA, Hodi FS, Buchbinder EI. Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol. 2015; 5:202. PMID: 26442214.
    Citations: 22     
  87. Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, Nishino M. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Oct; 3(10):1185-92. PMID: 26100356.
    Citations: 15     Fields:    Translation:Humans
  88. Lee JJ, Sholl LM, Lindeman NI, Granter SR, Laga AC, Shivdasani P, Chin G, Luke JJ, Ott PA, Hodi FS, Mihm MC, Lin JY, Werchniak AE, Haynes HA, Bailey N, Liu R, Murphy GF, Lian CG. Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. Clin Epigenetics. 2015; 7:59. PMID: 26221190.
    Citations: 16     Fields:    
  89. Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, Ng AK, Hodi FS, Schoenfeld JD. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015 Nov; 4(11):e1046028. PMID: 26451318.
    Citations: 35     
  90. Luke JJ, Donahue H, Nishino M, Giobbie-Hurder A, Davis M, Bailey N, Ott PA, Hodi FS. Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. Cancer Immunol Res. 2015 Sep; 3(9):986-91. PMID: 25943535.
    Citations: 1     Fields:    Translation:Humans
  91. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015 May 21; 372(21):2006-17. PMID: 25891304.
    Citations: 529     Fields:    Translation:Humans
  92. Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015 Feb 28; 6(6):3479-92. PMID: 25682878.
    Citations: 41     Fields:    Translation:Humans
  93. Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg J, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma. Cancer Immunol Res. 2015 Mar; 3(3):278-287. PMID: 25633712.
    Citations: 13     Fields:    Translation:HumansCellsPHPublic Health
  94. Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, Davis M, Carroll RS, Kaiser UB. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015 Feb 15; 21(4):749-55. PMID: 25538262.
    Citations: 22     Fields:    Translation:Humans
  95. Luke JJ, Ott PA, Shapiro GI. The biology and clinical development of MEK inhibitors for cancer. Drugs. 2014 Dec; 74(18):2111-28. PMID: 25414119.
    Citations: 6     Fields:    Translation:HumansCells
  96. Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, Simantov R, Crowley E, Green JA, Hawthorne T, Davis TA, Sznol M, Hwu P. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. J Clin Oncol. 2014 Nov 10; 32(32):3659-66. PMID: 25267741.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  97. Luke JJ, Ott PA. New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf. 2014; 6:77-88. PMID: 25018652.
    Citations: 7     
  98. Ott PA, Fritsch EF, Wu CJ, Dranoff G. Vaccines and melanoma. Hematol Oncol Clin North Am. 2014 Jun; 28(3):559-69. PMID: 24880947.
    Citations: 4     Fields:    Translation:HumansCells
  99. Fritsch EF, Rajasagi M, Ott PA, Brusic V, Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res. 2014 Jun; 2(6):522-9. PMID: 24894089.
    Citations: 48     Fields:    Translation:HumansCells
  100. Ott PA, Bhardwaj N. Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function. Front Immunol. 2013 Oct 28; 4:346. PMID: 24194739.
    Citations: 8     
  101. Luke JJ, Ott PA. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic? Expert Opin Pharmacother. 2013 Dec; 14(18):2457-62. PMID: 24138302.
    Citations: 8     Fields:    Translation:HumansAnimals
  102. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013 Oct 01; 19(19):5300-9. PMID: 24089443.
    Citations: 155     Fields:    Translation:Humans
  103. Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Oct 15; 119(20):3687-95. PMID: 23913718.
    Citations: 45     Fields:    Translation:Humans
  104. Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, Golfinos JG, Parker EC, Huang PP, Narayana A. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 2013 Jun; 23(3):191-5. PMID: 23462208.
    Citations: 48     Fields:    Translation:Humans
  105. Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, Chapman PB, Gnjatic S, Wolchok JD, Hodi FS, Carvajal RD. Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 2013 Jun; 18(6):726-32. PMID: 23716015.
    Citations: 19     Fields:    Translation:Humans
  106. Ott PA, Hodi FS. Treatment for advanced melanoma: new drugs, new opportunities, new challenges. Oncology (Williston Park). 2013 May; 27(5):381-92, 391. PMID: 25184259.
    Citations: 1     Fields:    Translation:Humans
  107. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, Parker EC, Ott PA, Pavlick AC. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol. 2013 Jul; 113(3):411-6. PMID: 23579338.
    Citations: 30     Fields:    Translation:Humans
  108. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74. PMID: 23569304.
    Citations: 111     Fields:    Translation:HumansCellsCTClinical Trials
  109. Ott PA, Hodi FS. The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention. Chin Clin Oncol. 2013 Mar; 2(1):7. PMID: 25841448.
    Citations: 3     Fields:    
  110. Ott PA, Henry T, Baranda SJ, Frleta D, Manches O, Bogunovic D, Bhardwaj N. Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. Cancer Immunol Immunother. 2013 Apr; 62(4):811-22. PMID: 23306863.
    Citations: 33     Fields:    Translation:HumansCells
  111. Ott PA, Provalov AV, Vazhenin AV, Nadvikova EA, Kandakova EIu, Zabolotskaia EG. [Long-term results of combined treatment of soft tissue sarcoma with the use of intraoperative radiotherapy]. Klin Med (Mosk). 2013; 91(3):65-7. PMID: 23789456.
    Citations:    Fields:    Translation:Humans
  112. Ott PA, Privalov AV, Vazhenin AV, Nadvikova EA, Lukina EIu, Komissarov AV, Zabolotskaia EG. [Immediate results of combined treatment for soft tissue sarcomas including intraoperative radiation therapy]. Vopr Onkol. 2013; 59(5):603-5. PMID: 24260888.
    Citations:    Fields:    Translation:Humans
  113. Ott PA, Privalov AV, Vazhenin AV, Chekha NA, Zabolotskaia EG, Komissarov AV. [Results of combined treatment with intraoperative radial therapy of soft tissue sarcoma]. Vestn Khir Im I I Grek. 2013; 172(1):99-101. PMID: 23808238.
    Citations:    Fields:    Translation:Humans
  114. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, Gonzalez R, Ott PA, Long GV, Gardner OS, Ouellet D, Xu Y, DeMarini DJ, Le NT, Patel K, Lewis KD. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 01; 31(4):482-9. PMID: 23248257.
    Citations: 123     Fields:    Translation:HumansCTClinical Trials
  115. Ott PA, Chang J, Madden K, Kannan R, Muren C, Escano C, Cheng X, Shao Y, Mendoza S, Gandhi A, Liebes L, Pavlick AC. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemother Pharmacol. 2013 Jan; 71(1):183-91. PMID: 23064957.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  116. Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, Bomalaski JS, Venhaus R, Pan L, Old LJ, Pavlick AC, Wolchok JD. Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs. 2013 Apr; 31(2):425-34. PMID: 22864522.
    Citations: 34     Fields:    Translation:HumansCTClinical Trials
  117. Ma MW, Medicherla RC, Qian M, Vega-Saenz de Miera E, Friedman EB, Berman RS, Shapiro RL, Pavlick AC, Ott PA, Bhardwaj N, Shao Y, Osman I, Darvishian F. Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. Mod Pathol. 2012 Jul; 25(7):1000-10. PMID: 22425909.
    Citations: 11     Fields:    Translation:Humans
  118. Seetharamu N, Tu TJ, Christos P, Ott PA, Berman RS, Shapiro RL, Osman I, Pavlick AC. Enrollment in clinical trials correlates with improved survival in metastatic melanoma. Oncology. 2011; 81(5-6):403-9. PMID: 22270052.
    Citations: 2     Fields:    Translation:Humans
  119. Chang JL, Ott PA, Sorlie C, Escano C, Yepes E, Mendoza S, Gandhi A, Liebes L, Pavlick AC. Abraxane, temozolomide, and oblimersen (The ATG Trial): A final report of toxicity and clinical efficacy in metastatic melanoma patients with normal lactate dehydrogenase (LDH). J Clin Oncol. 2011 May 20; 29(15_suppl):8545. PMID: 28021078.
  120. Ott PA, Adams S. Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. Immunotherapy. 2011 Feb; 3(2):213-27. PMID: 21322760.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  121. Ott PA, Berman RS. Surgical approach to primary cutaneous melanoma. Surg Oncol Clin N Am. 2011 Jan; 20(1):39-56. PMID: 21111958.
    Citations: 2     Fields:    Translation:Humans
  122. Ott PA, Hamilton A, Min C, Safarzadeh-Amiri S, Goldberg L, Yoon J, Yee H, Buckley M, Christos PJ, Wright JJ, Polsky D, Osman I, Liebes L, Pavlick AC. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One. 2010 Dec 29; 5(12):e15588. PMID: 21206909.
    Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
  123. Seetharamu N, Ott PA, Pavlick AC. Mucosal melanomas: a case-based review of the literature. Oncologist. 2010; 15(7):772-81. PMID: 20571149.
    Citations: 19     Fields:    Translation:Humans
  124. Ott PA, Hamilton A, Jones A, Haas N, Shore T, Liddell S, Christos PJ, Doyle LA, Millward M, Muggia FM, Pavlick AC. A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma. PLoS One. 2010 Jan 20; 5(1):e8714. PMID: 20098694.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  125. Seetharamu N, Ott PA, Pavlick AC. Novel therapeutics for melanoma. Expert Rev Anticancer Ther. 2009 Jun; 9(6):839-49. PMID: 19496721.
    Citations: 7     Fields:    Translation:HumansAnimals
  126. Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman E, Venhaus R, Pan L, Old L, Pavlick AC, Wolchok JD. Phase I/II study of arginine deiminase (ADI-PEG 20) in patients with advanced malignant melanoma (MM). J Clin Oncol. 2009 May 20; 27(15_suppl):9030. PMID: 27962087.
  127. Pavlick AC, Ott P, Escalon J, Madden K, Yepes E, Staha J, Mendoza S, Gandhi A, Yee H, Liebes L. Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel. J Clin Oncol. 2009 May 20; 27(15_suppl):9080. PMID: 27962199.
  128. Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. Chemotherapy. 2009; 55(4):221-7. PMID: 19451711.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  129. Ott P, Benke I, Stelzer J, Köhler C, Hanefeld M. ["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice]. Dtsch Med Wochenschr. 2009 Feb; 134(7):291-7. PMID: 19197810.
    Citations: 9     Fields:    Translation:Humans
  130. Ott PA, Pavlick AC, Zoloretev A, Ng B, Buckley MT, Brooks PP, Liebes L. Correlation of shedding cryptic epitope (HU177) levels and treatment response in sera of melanoma patients. J Clin Oncol. 2008 May 20; 26(15_suppl):20018. PMID: 27947817.
  131. Ott PA, Tary-Lehmann M, Lehmann PV. The secretory IFN-gamma response of single CD4 memory cells after activation on different antigen presenting cell types. Clin Immunol. 2007 Sep; 124(3):267-76. PMID: 17632036.
    Citations: 4     Fields:    Translation:AnimalsCells
  132. Hofstetter HH, Karulin AY, Forsthuber TG, Ott PA, Tary-Lehmann M, Lehmann PV. The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL/6 mice. J Neuroimmunol. 2005 Dec 30; 170(1-2):105-14. PMID: 16257061.
    Citations: 15     Fields:    Translation:AnimalsCells
  133. Quast S, Zhang W, Shive C, Kovalovski D, Ott PA, Herzog BA, Boehm BO, Tary-Lehmann M, Karulin AY, Lehmann PV. IL-2 absorption affects IFN-gamma and IL-5, but not IL-4 producing memory T cells in double color cytokine ELISPOT assays. Cell Immunol. 2005 Sep; 237(1):28-36. PMID: 16256965.
    Citations: 17     Fields:    Translation:HumansCells
  134. Ott PA, Anderson MR, Tary-Lehmann M, Lehmann PV. CD4+CD25+ regulatory T cells control the progression from periinsulitis to destructive insulitis in murine autoimmune diabetes. Cell Immunol. 2005 May; 235(1):1-11. PMID: 16122720.
    Citations: 8     Fields:    Translation:AnimalsCells
  135. Ott PA, Herzog BA, Quast S, Hofstetter HH, Boehm BO, Tary-Lehmann M, Durinovic-Bello I, Berner BR, Lehmann PV. Islet-cell antigen-reactive T cells show different expansion rates and Th1/Th2 differentiation in type 1 diabetic patients and healthy controls. Clin Immunol. 2005 Apr; 115(1):102-14. PMID: 15870028.
    Citations: 9     Fields:    Translation:HumansCells
  136. Herzog BA, Ott PA, Dittrich MT, Quast S, Karulin AY, Kalbacher H, Karges W, Tary-Lehmann M, Lehmann PV, Boehm BO, Durinovic-Belló I. Increased in vivo frequency of IA-2 peptide-reactive IFNgamma+/IL-4- T cells in type 1 diabetic subjects. J Autoimmun. 2004 Aug; 23(1):45-54. PMID: 15236752.
    Citations: 7     Fields:    Translation:HumansCells
  137. 40th EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004. Diabetologia. 2004 Aug; 47(Suppl 1):A1-A464. PMID: 27770180.
    Citations: 2     Fields:    
  138. Ott PA, Dittrich MT, Herzog BA, Guerkov R, Gottlieb PA, Putnam AL, Durinovic-Bello I, Boehm BO, Tary-Lehmann M, Lehmann PV. T cells recognize multiple GAD65 and proinsulin epitopes in human type 1 diabetes, suggesting determinant spreading. J Clin Immunol. 2004 Jul; 24(4):327-39. PMID: 15163889.
    Citations: 14     Fields:    Translation:HumansCells
  139. Ott PA, Berner BR, Herzog BA, Guerkov R, Yonkers NL, Durinovic-Bello I, Tary-Lehmann M, Lehmann PV, Anthony DD. CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases. J Immunol Methods. 2004 Feb 15; 285(2):223-35. PMID: 14980436.
    Citations: 13     Fields:    Translation:HumansCells
  140. Schloot NC, Meierhoff G, Karlsson Faresjö M, Ott P, Putnam A, Lehmann P, Gottlieb P, Roep BO, Peakman M, Tree T. Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. J Autoimmun. 2003 Dec; 21(4):365-76. PMID: 14624759.
    Citations: 18     Fields:    Translation:HumansCells
  141. Meierhoff G, Ott PA, Lehmann PV, Schloot NC. Cytokine detection by ELISPOT: relevance for immunological studies in type 1 diabetes. Diabetes Metab Res Rev. 2002 Sep-Oct; 18(5):367-80. PMID: 12397579.
    Citations: 8     Fields:    Translation:HumansAnimalsCells
  142. Dahl B, Schiødt FV, Ott P, Gvozdenovic R, Yin HL, Lee WM. Plasma gelsolin is reduced in trauma patients. Shock. 1999 Aug; 12(2):102-4. PMID: 10446889.
    Citations: 9     Fields:    Translation:HumansAnimalsCTClinical Trials
  143. Dahl B, Schiødt FV, Nielsen M, Kiaer T, Williams JG, Ott P. Admission level of Gc-globulin predicts outcome after multiple trauma. Injury. 1999 May; 30(4):275-81. PMID: 10476297.
    Citations: 3     Fields:    Translation:Humans
  144. Schiødt FV, Ott P, Bondesen S, Tygstrup N. Reduced serum Gc-globulin concentrations in patients with fulminant hepatic failure: association with multiple organ failure. Crit Care Med. 1997 Aug; 25(8):1366-70. PMID: 9267951.
    Citations: 2     Fields:    Translation:Humans
  145. Leander P, Hove LD, Ott P. [Who dies of morphine and dextropropoxyphene intoxication? Danish experiences from the period 1979-1992]. Ugeskr Laeger. 1997 Apr 14; 159(16):2370-4. PMID: 9163112.
  146. Clemmesen JO, Larsen FS, Ott P, Hansen BA. [Paracetamol poisoning at a department of hepatology]. Ugeskr Laeger. 1995 Feb 13; 157(7):877-80. PMID: 7701647.
    Citations:    Fields:    Translation:Humans
  147. Ovesen L, Lyduch S, Ott P. A simple technique for predicting maintenance dosage of warfarin--is it better than empirical dosing? Eur J Clin Pharmacol. 1989; 37(6):573-6. PMID: 2612552.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  148. Bütikofer P, Frenkel EJ, Ott P. 'Crossed immunoblotting': identification of proteins after crossed immunoelectrophoresis and electrotransfer to nitrocellulose membranes. J Immunol Methods. 1985 Nov 28; 84(1-2):65-71. PMID: 3905973.
    Citations: 1     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Ott's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (444)
Co-Authors (138)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.